Oxidized phospholipids impair pulmonary antibacterial defenses: Evidence in mice exposed to cigarette smoke

Biochemical and Biophysical Research Communications

Volumn 426, Issue 2, 2012, Pages 253-259

  Thimmulappa, Rajesh K ^a   Gang, Xing ^a   Kim, Jung Hyun ^a   Sussan, Thomas E ^a   Witztum, Joseph L ^b   Biswal, Shyam ^a  

^a Johns Hopkins University   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Bacteria; Cigarette smoke; COPD; Macrophages; Oxidized phospholipids; Phagocytosis

Indexed keywords

1 PALMITOYL 2 ARACHIDONOYLGLYCERO 3 PHOSPHORYLCHOLINE; CIGARETTE SMOKE; GLYCEROPHOSPHORYLCHOLINE DERIVATIVE; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BACTERIAL CLEARANCE; CONTROLLED STUDY; CYTOTOXICITY; IN VITRO STUDY; INNATE IMMUNITY; LIPID OXIDATION; LONG TERM EXPOSURE; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTOSIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; BRONCHOALVEOLAR LAVAGE FLUID; INHALATION EXPOSURE; LUNG; MACROPHAGES, ALVEOLAR; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PHAGOCYTOSIS; PHOSPHATIDYLCHOLINES; PHOSPHOLIPIDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING;

BACTERIA (MICROORGANISMS); MUS;

EID: 84866380215     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.076     Document Type: Article

References (31)

1. Barnes P.J. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med. 2007, 4:e112.
2. Hogg J.C., Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 2008.
3. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F., Wedzicha J.A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010, 363:1128-1138.
4. Sethi S., Evans N., Grant B.J., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002, 347:465-471.
5. Berenson C.S., Garlipp M.A., Grove L.J., Maloney J., Sethi S. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J. Infect. Dis. 2006, 194:1375-1384.
6. Donnelly L.E., Barnes P.J. Defective phagocytosis in airways disease. Chest 2012, 141:1055-1062.
7. Harvey C.J., Thimmulappa R.K., Sethi S., Kong X., Yarmus L., Brown R.H., Feller, Kopman D., Wise R., Biswal S. Targeting Nrf2 signaling improves bacterial clearance by alveolar macrophages in patients with COPD and in a mouse model. Sci. Transl. Med. 2011, 3:78ra32.
8. Drannik A.G., Pouladi M.A., Robbins C.S., Goncharova S.I., Kianpour S., Stampfli M.R. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 2004, 170:1164-1171.
9. Marti Lliteras P., Regueiro V., Morey P., Hood D.W., Saus C., Sauleda J., Agusti A.G., Bengoechea J.A., Garmendia J. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect. Immun. 2009, 77:4232-4242.
10. Phipps J.C., Aronoff D.M., Curtis J.L., Goel D., O'Brien E., Mancuso P. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect. Immun. 2010, 78:1214-1220.
11. Taylor A.E., Finney Hayward T.K., Quint J.K., Thomas C.M., Tudhope S.J., Wedzicha J.A., Barnes P.J., Donnelly L.E. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010, 35:1039-1047.
12. Pryor W.A., Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. N. Y. Acad Sci. 1993, 686:12-27. discussion 27-28.
13. Glasser J.R., Mallampalli R.K. Surfactant and its role in the pathobiology of pulmonary infection. Microbes. Infect. 2012, 14:17-25.
14. Fruhwirth G.O., Loidl A., Hermetter A. Oxidized phospholipids: from molecular properties to disease. Biochim. Biophys. Acta. 2007, 1772:718-736.
15. Kimura T., Shibata Y., Yamauchi K., Igarashi A., Inoue S., Abe S., Fujita K., Uosaki Y., Kubota I. Oxidized phospholipid, 1-palmitoyl-2-(9'-oxo-nonanoyl)-glycerophosphocholine (PON-GPC), produced in the lung due to cigarette smoking, impairs immune function in macrophages. Lung 2012, 190:169-182.
16. Rangasamy T., Cho C.Y., Thimmulappa R.K., Zhen L., Srisuma S.S., Kensler T.W., Yamamoto M., Petrache I., Tuder R.M., Biswal S. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 2004, 114:1248-1259.
17. A. Singh, T. Rangasamy, R.K. Thimmulappa, H. Lee, W.O. Osburn, Brigelius, R. Flohe, T.W. Kensler, M. Yamamoto, S. Biswal, Glutathione Peroxidase 2, the Major Cigarette Smoke-inducible Isoform of GPX in Lungs is Regulated by Nrf2, Am. J. Respir. Cell Mol. Biol. 35 (2006) 639-650.
18. Rahman I., van Schadewijk A.A., Crowther A.J., Hiemstra P.S., Stolk J., MacNee W., De Boer W.I. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002, 166:490-495.
19. Crowe C.R., Chen K., Pociask D.A., Alcorn J.F., Krivich C., Enelow R.I., Ross T.M., Witztum J.L., Kolls J.K. Critical role of IL-17RA in immunopathology of influenza infection. J. Immunol. 2009, 183:5301-5310.
20. Imai Y., Kuba K., Neely G.G., Yaghubian Malhami R., Perkmann T., van Loo G., Ermolaeva M., Veldhuizen R., Leung Y.H., Wang H., Liu H., Sun Y., Pasparakis M., Kopf M., Mech C., Bavari S., Peiris J.S., Slutsky A.S., Akira S., Hultqvist M., Holmdahl R., Nicholls J., Jiang C., Binder C.J., Penninger J.M. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008, 133:235-249.
21. Bochkov V.N., Kadl A., Huber J., Gruber F., Binder B.R., Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002, 419:77-81.
22. Nonas S., Miller I., Kawkitinarong K., Chatchavalvanich S., Gorshkova I., Bochkov V.N., Leitinger N., Natarajan V., Garcia J.G., Birukov K.G. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am. J. Respir. Crit. Care Med. 2006, 173:1130-1138.
23. Sussan T.E., Rangasamy T., Blake D.J., Malhotra D., El Haddad H., Bedja D., Yates M.S., Kombairaju P., Yamamoto M., Liby K.T., Sporn M.B., Gabrielson K.L., Champion H.C., Tuder R.M., Kensler T.W., Biswal S. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:250-255.
24. Garbin U., Fratta Pasini A., Stranieri C., Cominacini M., Pasini A., Manfro S., Lugoboni F., Mozzini C., Guidi G., Faccini G., Cominacini L. Cigarette smoking blocks the protective expression of Nrf2/ARE pathway in peripheral mononuclear cells of young heavy smokers favouring inflammation. PLoS ONE 2009, 4:e8225.
25. Greenberg M.E., Sun M., Zhang R., Febbraio M., Silverstein R., Hazen S.L. Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J. Exp. Med. 2006, 203:2613-2625.
26. Weismann D., Binder C.J. The innate immune response to products of phospholipid peroxidation. Biochim. Biophys. Acta. 1818, 2012:2465-2475.
27. Stemmer U., Ramprecht C., Zenzmaier E., Stojcic B., Rechberger G., Kollroser M., Hermetter A. Uptake and protein targeting of fluorescent oxidized phospholipids in cultured RAW 264.7 macrophages. Biochim. Biophys. Acta. 1821, 2012:706-718.
28. Horkko S., Bird D.A., Miller E., Itabe H., Leitinger N., Subbanagounder G., Berliner J.A., Friedman P., Dennis E.A., Curtiss L.K., Palinski W., Witztum J.L. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 1999, 103:117-128.
29. Boullier A., Friedman P., Harkewicz R., Hartvigsen K., Green S.R., Almazan F., Dennis E.A., Steinberg D., Witztum J.L., Quehenberger O. Phosphocholine as a pattern recognition ligand for CD36. J. Lipid Res. 2005, 46:969-976.
30. Kadl A., Meher A.K., Sharma P.R., Lee M.Y., Doran A.C., Johnstone S.R., Elliott M.R., Gruber F., Han J., Chen W., Kensler T., Ravichandran K.S., Isakson B.E., Wamhoff B.R., Leitinger N. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ. Res. 2010, 107:737-746.
31. Thimmulappa R.K., Scollick C., Traore K., Yates M., Trush M.A., Liby K.T., Sporn M.B., Yamamoto M., Kensler T.W., Biswal S. Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem. Biophys. Res. Commun. 2006, 351:883-889.